Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide
Summary
Characterized the pharmacological properties of GHRP-2 (KP-102), demonstrating its potent and specific growth hormone-releasing activity through the ghrelin receptor (GHS-R1a). Established dose-response relationships and receptor binding profiles.
Key Findings
- GHRP-2 demonstrated potent GH-releasing activity via GHS-R1a receptor binding
- Dose-dependent stimulation of growth hormone secretion established
- Receptor binding profile confirmed specificity for ghrelin receptor pathway
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Robust GH responses to GHRP-2 stimulation test in adolescents with obesity
Onuki T, Kato Y, Hasegawa T, et al.
Journal of Pediatric Endocrinology and Metabolism
Evaluated growth hormone responses to GHRP-2 stimulation testing in adolescents with obesity. Found that GHRP-2 elicited robust GH responses even in obese subjects, suggesting it may be a more reliable diagnostic tool for GH deficiency assessment than conventional provocative tests.
- GHRP-2 produced robust GH responses in obese adolescents where other tests showed blunted responses
- May serve as a more reliable GH deficiency diagnostic tool in obese populations
Anti-inflammatory effect of the growth hormone-releasing peptide, GHRP-2, in arthritic rats
Granado M, Priego T, Martín AI, et al.
American Journal of Physiology-Endocrinology and Metabolism
Demonstrated that GHRP-2 exerts significant anti-inflammatory effects in an adjuvant-induced arthritis rat model. Treatment reduced circulating inflammatory markers and attenuated arthritis-induced muscle wasting, suggesting therapeutic potential beyond growth hormone secretion.
- GHRP-2 significantly reduced inflammation in adjuvant-induced arthritis model
- Attenuated arthritis-induced body weight loss and muscle wasting